These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25880553)

  • 1. Drying anti-malarial drugs in vitro tests to outsource SYBR green assays.
    Traore K; Lavoignat A; Bonnot G; Sow F; Bess GC; Chavant M; Gay F; Doumbo O; Picot S
    Malar J; 2015 Feb; 14():90. PubMed ID: 25880553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from Cambodia.
    Chaorattanakawee S; Tyner SD; Lon C; Yingyuen K; Ruttvisutinunt W; Sundrakes S; Sai-gnam P; Johnson JD; Walsh DS; Saunders DL; Lanteri CA
    Malar J; 2013 Jul; 12():239. PubMed ID: 23849006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers.
    Lim P; Dek D; Try V; Eastman RT; Chy S; Sreng S; Suon S; Mao S; Sopha C; Sam B; Ashley EA; Miotto O; Dondorp AM; White NJ; Su XZ; Char MC; Anderson JM; Amaratunga C; Menard D; Fairhurst RM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5277-83. PubMed ID: 23939897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
    Bacon DJ; Latour C; Lucas C; Colina O; Ringwald P; Picot S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1172-8. PubMed ID: 17220424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.
    Quashie NB; Duah NO; Abuaku B; Quaye L; Ayanful-Torgby R; Akwoviah GA; Kweku M; Johnson JD; Lucchi NW; Udhayakumar V; Duplessis C; Kronmann KC; Koram KA
    Malar J; 2013 Dec; 12():450. PubMed ID: 24341604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.
    Pascual A; Parola P; Benoit-Vical F; Simon F; Malvy D; Picot S; Delaunay P; Basset D; Maubon D; Faugère B; Ménard G; Bourgeois N; Oeuvray C; Didillon E; Rogier C; Pradines B
    Malar J; 2012 Feb; 11():45. PubMed ID: 22333675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved SYBR Green-1-based fluorescence method for the routine monitoring of Plasmodium falciparum resistance to anti-malarial drugs.
    Dery V; Duah NO; Ayanful-Torgby R; Matrevi SA; Anto F; Quashie NB
    Malar J; 2015 Dec; 14():481. PubMed ID: 26625907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity.
    Karl S; Wong RP; St Pierre TG; Davis TM
    Malar J; 2009 Dec; 8():294. PubMed ID: 20003396
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Agarwal P; Anvikar AR; Pillai CR; Srivastava K
    Indian J Med Res; 2017 Nov; 146(5):622-628. PubMed ID: 29512604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.
    Pascual A; Madamet M; Briolant S; Gaillard T; Amalvict R; Benoit N; Travers D; Pradines B;
    Malar J; 2015 Feb; 14():49. PubMed ID: 25848972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Worldwide Antimalarial Resistance Network Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field Samples with Various Initial Parasitemia Levels.
    Cheruiyot AC; Auschwitz JM; Lee PJ; Yeda RA; Okello CO; Leed SE; Talwar M; Murthy T; Gaona HW; Hickman MR; Akala HM; Kamau E; Johnson JD
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2417-24. PubMed ID: 26856829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand.
    Chaorattanakawee S; Lon C; Jongsakul K; Gawee J; Sok S; Sundrakes S; Kong N; Thamnurak C; Chann S; Chattrakarn S; Praditpol C; Buathong N; Uthaimongkol N; Smith P; Sirisopana N; Huy R; Prom S; Fukuda MM; Bethell D; Walsh DS; Lanteri C; Saunders D
    Malar J; 2016 Oct; 15(1):519. PubMed ID: 27769299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.
    Akala HM; Eyase FL; Cheruiyot AC; Omondi AA; Ogutu BR; Waters NC; Johnson JD; Polhemus ME; Schnabel DC; Walsh DS
    Am J Trop Med Hyg; 2011 Jul; 85(1):34-41. PubMed ID: 21734121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.
    Traoré K; Diakité SAS; Bah S; Konaté DS; Dabitao D; Sanogo I; Sangaré M; Dama S; Keita B; Doumbouya M; Guindo MA; Doumbia S; Diakité M
    Drugs R D; 2020 Sep; 20(3):249-255. PubMed ID: 32557086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SYBR
    Leidenberger M; Voigtländer C; Simon N; Kappes B
    Methods Mol Biol; 2017; 1601():97-110. PubMed ID: 28470521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change.
    Tinto H; Bonkian LN; Nana LA; Yerbanga I; Lingani M; Kazienga A; Valéa I; Sorgho H; Kpoda H; Guiguemdé TR; Ouédraogo JB; Mens PF; Schallig H; D'Alessandro U
    Malar J; 2014 May; 13():207. PubMed ID: 24885950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance.
    Chaorattanakawee S; Saunders DL; Sea D; Chanarat N; Yingyuen K; Sundrakes S; Saingam P; Buathong N; Sriwichai S; Chann S; Se Y; Yom Y; Heng TK; Kong N; Kuntawunginn W; Tangthongchaiwiriya K; Jacob C; Takala-Harrison S; Plowe C; Lin JT; Chuor CM; Prom S; Tyner SD; Gosi P; Teja-Isavadharm P; Lon C; Lanteri CA
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4631-43. PubMed ID: 26014942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.
    Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I
    Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season.
    Fall B; Camara C; Fall M; Nakoulima A; Dionne P; Diatta B; Diemé Y; Wade B; Pradines B
    Malar J; 2015 Feb; 14():60. PubMed ID: 25849097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs.
    Fall B; Diawara S; Sow K; Baret E; Diatta B; Fall KB; Mbaye PS; Fall F; Diémé Y; Rogier C; Wade B; Bercion R; Pradines B
    Malar J; 2011 Oct; 10():310. PubMed ID: 22014157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.